Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(9):4067-4080. doi:10.7150/thno.72948 This issue Cite

Review

Current update on theranostic roles of cyclophilin A in kidney diseases

Sudarat Hadpech, Visith Thongboonkerd✉

Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

✉ Corresponding author: Prof. Visith Thongboonkerd, Head of Medical Proteomics Unit, Office for Research and Development, Siriraj Hospital, Mahidol University, 6th Floor - SiMR Building, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand. Phone: +66 More

Citation:
Hadpech S, Thongboonkerd V. Current update on theranostic roles of cyclophilin A in kidney diseases. Theranostics 2022; 12(9):4067-4080. doi:10.7150/thno.72948. https://www.thno.org/v12p4067.htm
Other styles

File import instruction

Abstract

Graphic abstract

Cyclophilin A (CyPA) or peptidylprolyl isomerase A (PPIA), an immunophilin with peptidyl-prolyl cis/trans isomerase (PPIase) activity, is an abundant cellular protein widely expressed across various cell types and tissues, including the kidney. Expression of CyPA in the kidney is relatively higher in proximal tubular epithelial cells than others along the nephron. Alterations in expression and secretion of CyPA play important roles in physiological processes and pathophysiology of several diseases affecting the kidney. Herein, we provide a brief overview of CyPA structural biology and present the current update on its theranostic roles in various kidney diseases, including diabetic nephropathy, acute kidney injury, chronic kidney disease, renal fibrosis, and nephrotoxicity associated with organ transplantation. Notably, the diagnostic/prognostic role for urinary CyPA in several of these kidney diseases is promising. Finally, future perspectives on the CyPA research, especially targeting CyPA for therapeutics, are discussed. A comprehensive understanding of the theranostic roles of CyPA in kidney diseases is expected to provide novel insights into the design of new therapeutic interventions and prevention strategies.

Keywords: AKI, Biomarker, CKD, Diabetic nephropathy, Nephrotoxicity, PPIA, Renal fibrosis, Therapeutics

Citation styles

APA
Hadpech, S., Thongboonkerd, V. (2022). Current update on theranostic roles of cyclophilin A in kidney diseases. Theranostics, 12(9), 4067-4080. https://doi.org/10.7150/thno.72948.

ACS
Hadpech, S.; Thongboonkerd, V. Current update on theranostic roles of cyclophilin A in kidney diseases. Theranostics 2022, 12 (9), 4067-4080. DOI: 10.7150/thno.72948.

NLM
Hadpech S, Thongboonkerd V. Current update on theranostic roles of cyclophilin A in kidney diseases. Theranostics 2022; 12(9):4067-4080. doi:10.7150/thno.72948. https://www.thno.org/v12p4067.htm

CSE
Hadpech S, Thongboonkerd V. 2022. Current update on theranostic roles of cyclophilin A in kidney diseases. Theranostics. 12(9):4067-4080.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use